|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.94 USD | -0.68% |
|
-0.87% | -0.61% |
| Dec. 12 | AstraZeneca: Lynparza shows promise in breast cancer | CF |
| Dec. 12 | Stock market giants pressure suppliers with extreme payment times - Di | FW |
| Capitalization | 208B 198B 185B 164B 295B 17,660B 326B 2,286B 847B 7,260B 782B 764B 31,676B | P/E ratio 2024 * |
24.7x | P/E ratio 2025 * | 20.4x |
|---|---|---|---|---|---|
| Enterprise value | 231B 220B 205B 182B 327B 19,580B 361B 2,534B 940B 8,049B 867B 847B 35,119B | EV / Sales 2024 * |
4.34x | EV / Sales 2025 * | 3.95x |
| Free-Float |
96.63% | Yield 2024 * |
2.31% | Yield 2025 * | 2.44% |
More valuation ratios
* Estimated data
More news
Last Transcript: AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | -0.68% | ||
| 1 week | -0.87% | ||
| Current month | -1.01% | ||
| 1 month | +2.68% | ||
| 3 months | -15.22% | ||
| 6 months | -16.40% | ||
| Current year | -0.61% |
1 week
66.92
69.00
1 month
62.7569.00
Current year
60.4787.68
1 year
60.4787.68
3 years
52.6587.68
5 years
36.1587.68
10 years
25.5587.68
| Director | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 2012-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 2021-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 2019-12-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 1999-04-05 | |
Pascal Soriot
BRD | Director/Board Member | 64 | 2012-09-30 |
Philip Broadley
BRD | Director/Board Member | 63 | 2017-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.38% | 9 M€ | -4.31% | - | |
| 0.99% | 1,174 M€ | +12.20% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.68% | -0.87% | - | - | 208B | ||
| -1.72% | -5.24% | +33.79% | +220.45% | 717B | ||
| -0.73% | +1.75% | +18.68% | +108.92% | 492B | ||
| -0.27% | -2.19% | -5.69% | -11.63% | 353B | ||
| -0.68% | -1.69% | +13.02% | +38.03% | 308B | ||
| +1.50% | -2.22% | -2.98% | +39.42% | 252B | ||
| -0.16% | -0.31% | +0.71% | -32.23% | 232B | ||
| +0.14% | -2.57% | +2.48% | +17.95% | 199B | ||
| +0.24% | -0.10% | +0.03% | +29.95% | 147B | ||
| +0.55% | -1.28% | -11.23% | -51.93% | 143B | ||
| Average | +0.03% | -1.62% | +5.42% | +39.88% | 315.93B | |
| Weighted average by Cap. | -0.04% | -2.00% | +11.86% | +78.15% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 53.11B 50.63B 47.18B 41.81B 75.34B 4,507B 83.21B 583B 216B 1,853B 200B 195B 8,084B | 56.95B 54.3B 50.59B 44.84B 80.79B 4,833B 89.22B 626B 232B 1,987B 214B 209B 8,669B |
| Net income | 8.36B 7.97B 7.43B 6.58B 11.86B 710B 13.1B 91.84B 34.05B 292B 31.42B 30.71B 1,273B | 10.15B 9.67B 9.01B 7.99B 14.39B 861B 15.9B 111B 41.32B 354B 38.13B 37.27B 1,545B |
| Net Debt | 22.62B 21.56B 20.09B 17.81B 32.09B 1,919B 35.43B 248B 92.1B 789B 84.99B 83.08B 3,443B | 17.01B 16.22B 15.11B 13.39B 24.13B 1,443B 26.65B 187B 69.26B 593B 63.91B 62.47B 2,589B |
More financial data
* Estimated data
Employees
89,900
Sector
Pharmaceuticals
Calendar
2025-02-05
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-12 | 66.94 $ | -0.68% | 4,789,147 |
| 24-12-11 | 67.40 $ | +0.33% | 7,351,804 |
| 24-12-10 | 67.18 $ | -2.04% | 3,960,299 |
| 24-12-09 | 68.58 $ | +0.56% | 5,791,049 |
| 24-12-06 | 68.20 $ | +0.99% | 6,815,482 |
Delayed Quote Nasdaq, December 12, 2024 at 04:00 pm EST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
134.23USD
Average target price
177.13USD
Spread / Average Target
+31.96%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
- AZN Stock